(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 8.53% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 85.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.87%.
Incyte's revenue in 2025 is $4,584,996,000.On average, 10 Wall Street analysts forecast INCY's revenue for 2025 to be $943,406,980,984, with the lowest INCY revenue forecast at $909,951,685,994, and the highest INCY revenue forecast at $957,261,237,643. On average, 10 Wall Street analysts forecast INCY's revenue for 2026 to be $1,047,950,408,523, with the lowest INCY revenue forecast at $1,000,312,792,950, and the highest INCY revenue forecast at $1,103,607,038,990.
In 2027, INCY is forecast to generate $1,143,084,455,016 in revenue, with the lowest revenue forecast at $1,039,993,881,995 and the highest revenue forecast at $1,275,864,032,018.